Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

663 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants.
Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C; Type 1 Diabetes TrialNet Study Group. Meah FA, et al. Among authors: geyer s. Diabetologia. 2016 Jun;59(6):1186-95. doi: 10.1007/s00125-016-3924-5. Epub 2016 Mar 19. Diabetologia. 2016. PMID: 26995649 Free PMC article.
Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?
Steck AK, Xu P, Geyer S, Redondo MJ, Antinozzi P, Wentworth JM, Sosenko J, Onengut-Gumuscu S, Chen WM, Rich SS, Pugliese A; Type 1 Diabetes TrialNet Study Group. Steck AK, et al. Among authors: geyer s. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2873-2880. doi: 10.1210/jc.2016-4003. J Clin Endocrinol Metab. 2017. PMID: 28520980 Free PMC article.
Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives.
Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, Henderson C, Kinderman A, Sosenko JM, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group. Bosi E, et al. Among authors: geyer s. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2881-2886. doi: 10.1210/jc.2017-00569. J Clin Endocrinol Metab. 2017. PMID: 28531305 Free PMC article.
The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1.
Sosenko JM, Geyer S, Skyler JS, Rafkin LE, Ismail HM, Libman IM, Liu YF, DiMeglio LA, Evans-Molina C, Palmer JP. Sosenko JM, et al. Among authors: geyer s. Pediatr Diabetes. 2018 May;19(3):403-409. doi: 10.1111/pedi.12609. Epub 2017 Nov 24. Pediatr Diabetes. 2018. PMID: 29171129 Free PMC article. Clinical Trial.
β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis.
Evans-Molina C, Sims EK, DiMeglio LA, Ismail HM, Steck AK, Palmer JP, Krischer JP, Geyer S, Xu P, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Evans-Molina C, et al. Among authors: geyer s. JCI Insight. 2018 Aug 9;3(15):e120877. doi: 10.1172/jci.insight.120877. eCollection 2018 Aug 9. JCI Insight. 2018. PMID: 30089716 Free PMC article.
Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables.
Wentworth JM, Bediaga NG, Giles LC, Ehlers M, Gitelman SE, Geyer S, Evans-Molina C, Harrison LC; Type 1 Diabetes TrialNet Study Group; Immune Tolerance Network Study Group. Wentworth JM, et al. Among authors: geyer s. Diabetologia. 2019 Jan;62(1):33-40. doi: 10.1007/s00125-018-4722-z. Epub 2018 Aug 30. Diabetologia. 2019. PMID: 30167735 Free PMC article. Review.
Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes.
Redondo MJ, Steck AK, Sosenko J, Anderson M, Antinozzi P, Michels A, Wentworth JM, Atkinson MA, Pugliese A, Geyer S; Type 1 Diabetes TrialNet Study Group. Redondo MJ, et al. Among authors: geyer s. Diabetes Care. 2018 Dec;41(12):2480-2486. doi: 10.2337/dc18-0861. Epub 2018 Oct 1. Diabetes Care. 2018. PMID: 30275285 Free PMC article.
Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention.
Sims EK, Geyer S, Johnson SB, Libman I, Jacobsen LM, Boulware D, Rafkin LE, Matheson D, Atkinson MA, Rodriguez H, Spall M, Elding Larsson H, Wherrett DK, Greenbaum CJ, Krischer J, DiMeglio LA; Type 1 Diabetes TrialNet Study Group. Sims EK, et al. Among authors: geyer s. Diabetes Care. 2019 Dec;42(12):2228-2236. doi: 10.2337/dc19-0593. Epub 2019 Sep 26. Diabetes Care. 2019. PMID: 31558546 Free PMC article.
The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening.
Jacobsen LM, Bocchino L, Evans-Molina C, DiMeglio L, Goland R, Wilson DM, Atkinson MA, Aye T, Russell WE, Wentworth JM, Boulware D, Geyer S, Sosenko JM. Jacobsen LM, et al. Among authors: geyer s. Diabetologia. 2020 Mar;63(3):588-596. doi: 10.1007/s00125-019-05047-w. Epub 2019 Nov 25. Diabetologia. 2020. PMID: 31768570 Free PMC article.
Index60 as an additional diagnostic criterion for type 1 diabetes.
Redondo MJ, Nathan BM, Jacobsen LM, Sims E, Bocchino LE, Pugliese A, Schatz DA, Atkinson MA, Skyler J, Palmer J, Geyer S, Sosenko JM; Type 1 diabetes TrialNet Study Group. Redondo MJ, et al. Among authors: geyer s. Diabetologia. 2021 Apr;64(4):836-844. doi: 10.1007/s00125-020-05365-4. Epub 2021 Jan 26. Diabetologia. 2021. PMID: 33496819 Free PMC article.
663 results